A Phase 1 interventional study of Soquelitinib in Hidradenitis Suppurativa (HS), sponsored by Corvus Pharmaceuticals, Inc.. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Corvus Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 86th largest by planned enrollment of the 139 interventional ones that give a count, is one of 17 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 33 of the 54 other live ones, and was the 158th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
Spyre Therapeutics, Inc. · Sites in United States, Canada
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
Corvus Pharmaceuticals, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Corvus Pharmaceuticals, Inc. has 1 study filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa
A Phase 1b, Open-label Study Evaluating the Safety and Efficacy of Oral Soquelitinib in Adults with Moderate-to-Severe Hidradenitis Suppurativa
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive open-label single arm of active tablets orally twice daily for 84 days.
Drug: Soquelitinib
Tablets
Also known as: CPI-818
Incidence of adverse events, changes in laboratory values, vital signs, and ECGs
Incidence, nature, and severity of treatment-emergent adverse events of soquelitinib, including changes in laboratory values, vital signs, and ECGs
Time frame: up to 30 days after last intervention administration
1) percentage of participants achieving HiSCR50 2) percentage of participants achieving HiSCR75 3) percentage of participants achieving HiSCR90
HiSCR is a validated clinical endpoint used to assess the inflammatory signs and symptoms of HS. HiSCR evaluation is based in count of active HS lesions including abscesses, inflammatory nodules and draining tunnels (fistulas). The sum of abscesses and inflammatory nodules constitutes the total AN count.
Time frame: Week 12
Efficacy as measured by Hidradenitis Suppurativa Severity Score System (IHS4)
IHS4 captures the inflammatory burden of draining tunnels, inflammatory nodules and abscesses. Different weights are assigned to each lesion type: inflammatory nodules (1 point), abscesses (2 points), and draining tunnels (4 points). The number of each lesion type is multiplied by its respective weight, and the three obtained values are then summed to obtain the total IHS4 score.
Time frame: Week 12
Efficacy as measured by change and percentage change in lesion count
Lesion count includes abscess count, inflammatory nodule count, abscess and inflammatory nodule \[AN\] count, draining tunnel count
Time frame: Week 12
1) at least 30% reduction and at least 1-pt reduction and 2) at least 3-pt reduction from Baseline in the weekly average of daily HS-Skin Pain NRS
The Skin Pain-NRS is used to assess participants self-reported severity of worst skin pain each day. The NRS is an 11-point scale (0 to 10), with 0 indicating "no pain" and 10 indicating the "worst pain imaginable" in a 24-hour recall period.
Time frame: Week 12
Evaluate change from baseline in Hidradenitis Suupurativa Quality of Life (HiSQoL) Score
HiSQoL is 17-item questionnaire to assess HS-specific health-related quality of life which has a recall period of 7 days. The HiSQoL includes 3 subscales: symptom status, psychosocial impact, and impact on physical activities. Individual item scores are summed and a total score ranging from 0 to 68 is calculated, where the higher the score the more impact HS has on quality of life.
Time frame: Week 12
Evaluate change from baseline in Dermatology Life Quality Index (DLQI)
DLQI is a 10-item, validated, quality of life questionnaire. Participants assess their quality of life across 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment). Response options with corresponding scores are "not at all" (0), "a lot" (1), and "very much" (3), and "not relevant" or unanswered responses scored as 0. Participants with higher total scores indicate greater impairment of quality of life. A 4-point change from Baseline is considered the minimal clinically important difference threshold
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 20 phase 1 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Soquelitinib
Corvus Pharmaceuticals, Inc.